Insider trade

Officer sold ~$3.2M of JAZZ shares in the open market

Traded Feb 26, 2026 · Filed Mar 3, 2026

Why it stands out

Jazz Pharmaceuticals's & Chief Legal Officer sold $3.2M of Jazz Pharmaceuticals shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$1M+

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$3,196,335

Shares × reported transaction price

Timing vs results

2 days after results of Feb 24, 2026, 68 days before results of May 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−0.4%	−0.5%	+0.1%
30 days	+0.1%	−3.6%	+3.8%
90 days	+24.6%	+11.5%	+13.1%
180 days	+34.3%	+12.8%	+21.5%

Past results only. Not a forecast.

Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $192.1100 to $193.0100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.